GlobeNewswire by notified

Americhem udvider anlægget til fremstilling af materialer af medicinsk kvalitet for at imødekomme den stigende europæiske efterspørgsel

Del

RIBE, Danmark, May 22, 2023 (GLOBE NEWSWIRE) -- Americhem, Inc., en global industrileder inden for innovative polymerblanding, meddelte i dag, at virksomheden har afsluttet udvidelsen af sin produktionsanlæg i Danmark, som omfatter et rent fremstillingsanlæg dedikeret til materialer af medicinsk kvalitet. Udvidelsen forbedrer Americhems muligheder for at imødekomme den stigende efterspørgsel fra den europæiske sundhedsindustri efter polymermaterialer af høj kvalitet.

For at fejre færdiggørelsen af deres anlægsudvidelse vil Americhem afholde en åbningsceremoni på anlægget i Ribe, Danmark. Gæsterne vil omfatte virksomhedsledere fra Americhem, lokale og globale kunder samt repræsentanter for nyheder og medier.

Det nye anlæg på 1394 kvm. vil indeholde nye produktionslinjer, laboratorier til kvalitetskontrol, kontorer, plads til kundemøder og fællesområder for personalet. Det vil tilføje en ekstra produktionskapacitet på 5000 tons årligt, hvilket næsten fordobler kapaciteten på det eksisterende anlæg. Det nye rene miljø kombineret med Americhems ISO 13485:2016-certificering, der blev opnået i begyndelsen af 2023, giver Americhem unikke muligheder for at producere blandinger, der opfylder de strengeste krav til medicinsk udstyr. Derudover vil der blive foretaget en ISO 14644-1:2015-vurdering, når det nye produktionsanlæg er færdiggjort, og når de første ordrer er blevet fremstillet.

Americhem har kapacitet til at sammensætte materialer som PP, ABS, PA, PEEK, PC, TPE/TPU, EVA og POM, som alle kan leveres globalt for at tilfredsstille OEM'er over hele verden.

"Denne investering i Europa er en opfølgning på overtagelsen af Controlled Polymers A/S i 2020 og styrker Americhems engagement ikke kun i sundhedssektoren, men også i Europa", siger Barto DuPlessis, Americhems administrerende direktør i Europa. Det udvidede anlæg i Danmark vil også fungere som Americhems hovedkvarter for den europæiske region. Denne udvidelse er også et resultat af den forventede tocifrede vækst inden for det europæiske sundhedsmarked i perioden 2023-2028. Americhem ønskede også at have et anlæg i Europa for at kunne holde trit med den stadigt skiftende strenge overholdelse af regler som f.eks. REACH-bestemmelserne, der ofte revideres og opdateres. Stigende krav til overholdelse af bæredygtighed giver en yderligere dimension i forhold til overholdelse af lovgivningen, hvilket øger behovet for yderligere differentiering.

"Etableringen af den strategiske division Americhem Healthcare, den nye udvidelse i Danmark samt udvidelsen af vores anlæg i Morrisville, Pennsylvania i 2021, understøtter i høj grad vores strategi 'Global Reach, Regional Focus'. Vi ser frem til at arbejde sammen med virksomheder inden for sundhedspleje/medicinsk udstyr over hele verden for at løse deres applikationsudfordringer og for positivt at påvirke patientbehandlingen," siger John Richard, Americhems administrerende direktør.

Om Americhem
Americhem er en innovativ, teknologidrevet leder inden for den globale polymerindustri. Deres fundament er bygget op omkring levering af ydeevne, løsninger og tillid gennem et tæt samarbejde med kunderne. Alle virksomhedens produkter er bakket op af en omfattende teknisk support, der sikrer kvalitet, pålidelighed og værdi. Americhem råder over 10 produktionsanlæg og har salgskontorer over hele verden.

KONTAKTER

Sophie Zhou
Direktør, strategisk markedsføring og markedsføringskommunikation
Americhem
swzhou@americhem.com

Et billede, der ledsager denne meddelelse, findes på https://www.globenewswire.com/NewsRoom/AttachmentNg/62d8ba85-a153-40fc-a064-f082e203a4e4

For at se dette indhold fra www.globenewswire.com, så skal du give din accept på toppen af denne side.
For at se dette indhold fra ml.globenewswire.com, så skal du give din accept på toppen af denne side.

Information om GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Følg pressemeddelelser fra GlobeNewswire by notified

Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.

Flere pressemeddelelser fra GlobeNewswire by notified

Fortuna reports financial results for the first quarter of 20248.5.2024 04:11:05 CEST | Press release

(All amounts are expressed in US dollars, tabular amounts in millions, unless otherwise stated) VANCOUVER, British Columbia, May 07, 2024 (GLOBE NEWSWIRE) -- Fortuna Silver Mines Inc. (NYSE: FSM) (TSX: FVI) (“Fortuna” or the “Company”) today reported its financial and operating results for the first quarter of 2024. First Quarter 2024 highlights Financial Attributable net income of $26.3 million or $0.09 per share, compared to a $92.3 million attributable net loss or $0.30 per share in Q4 2023Adjusted attributable net income1 of $26.7 million or $0.09 per share, compared to $20.6 million or $0.07 per share in Q4 2023Generated $84.3 million of cash flow from operations before working capital changes, and free cash flow from ongoing operations1 of $12.1 million, compared to $105.4 million and $66.2 million, respectively, in Q4 2023The Company paid down $40.0 million of its revolving credit facility. At the close of the quarter total net debt was $83.0 million and the total net debt to ad

GXO Reports First Quarter 2024 Results7.5.2024 22:30:00 CEST | Press release

First quarter revenue of $2.5 billion, up 6% year over year; organic revenue growth1 of 1%Signed new business wins of approximately $250 million in annualized revenue in 1Q 2024; up 55% year over yearSales pipeline at 12-month high of $2.2 billionCompleted acquisition of Wincanton on April 29, 2024 GREENWICH, Conn., May 07, 2024 (GLOBE NEWSWIRE) -- GXO Logistics, Inc. (NYSE: GXO) today announced results for the first quarter 2024. Malcolm Wilson, chief executive officer of GXO, said, “We delivered a strong start to 2024, reflecting our solid execution amid improving industry dynamics. The company grew revenue by 6% to $2.5 billion and delivered positive organic revenue growth, while gaining market share. We look forward to driving continued growth throughout 2024 and are on track to achieve our full-year outlook. “We’re seeing strengthening demand from global blue-chip customers to realize operational efficiencies today while planning fulfillment strategies to meet their future needs.

DBV Technologies Reports First Quarter 2024 Financial Results and Business Update7.5.2024 22:30:00 CEST | Press release

Montrouge, France, May 7, 2024 DBV Technologies Reports First Quarter 2024 Financial Results and Business Update VITESSE enrollment on track to screen last patient by Q3 2024Appointment of Robert Pietrusko, PharmD to Chief Regulatory OfficerQ1 2024 closes with a cash balance of $101.5 million DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need, today reported financial results for the first quarter 2024. The quarterly financial statements were approved by the Board of Directors on May 7, 2024. Recent Business Developments Clinical and Regulatory Update Enrollment for VITESSE, DBV’s Phase 3 pivotal study of the modified Viaskin Peanut patch in children ages 4 through 7 years with peanut allergy passed the halfway point for recruitment in Q1 and continues to be on track to screen the last patient by

SFL - Invitation to Presentation of Q1 2024 Results7.5.2024 22:19:00 CEST | Press release

SFL Corporation Ltd. ("SFL" or the “Company”) (NYSE: SFL) plans to release its preliminary financial results for the first quarter of 2024 on Tuesday, May 14, 2024. SFL plans to host a conference call and webcast for all stakeholders and interested parties on Tuesday, May 14, 2024, at 10:00 AM (EST) / 4:00 PM (CET). Relevant material will on the same day be available from the Investor Relations section of the Company’s website at www.sflcorp.com. In order to listen to the conference call and presentation, you may do one of the following: A: Join Conference CallWebcast In Listen Only Mode: Visit the Investor Relations section of the Company’s website at www.sflcorp.com and click on the link to "Webcast", or access directly via the webcast link below. The webcast with slideshow will be played live from this platform: SFL Corporation Ltd. Q1 2024 Webcast B: Join Conference Call AndParticipate in Live Q&AthroughZoom: Join through the Zoom link below to ask a question: SFL Q1 2024 Q&A Meeti

Oculis Publishes Invitation to the Annual General Meeting7.5.2024 22:05:00 CEST | Press release

Zug, Switzerland, May 07, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq Global Market: OCS) (“Oculis”), has published the invitation to the 2024 Annual General Meeting, which will be held on 29 May 2024 at Ochsen-Zug, Kolinplatz 11, CH-6300 Zug, Switzerland, at 3:30 p.m. CEST / 9:30 a.m. EDT. All information pertaining to the 2024 Annual General Meeting, including meeting materials, can be accessed on the Oculis website at https://investors.oculis.com/events-presentations. About Oculis Oculis is a global biopharmaceutical company (Nasdaq: OCS) purposefully driven to save sight and improve eye care. Oculis’ highly differentiated pipeline comprises multiple innovative product candidates in development. It includes OCS-01, a topical eye drop candidate for diabetic macular edema (DME) and for the treatment of inflammation and pain following cataract surgery; OCS-02 (licaminlimab), a topical biologic anti-TNFα eye drop candidate for dry eye disease (DED) and for non-infectious anterior

HiddenA line styled icon from Orion Icon Library.Eye